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Prostate  cancer  is a leading  cause  of  cancer  death  in  men  in  developed  countries.  Once  the  tumor  has
achieved  a  castration-refractory  metastatic  stage,  treatment  options  are  limited  with  the  average  survival
of patients  ranging  from  two to three  years  only.  Recently,  new  drugs  for treatment  of castration-resistant
prostate  cancer  (CRPC)  have  been  approved,  and others  are  in  an advanced  stage  of  clinical  testing.  In this
review  we  provide  an overview  of the new  therapeutic  agents  that  arrived  in the clinical  praxis  or  are
tested  in  clinical  studies  and their mode  of  action  including  hormone  synthesis  inhibitors,  new  androgenastration-resistant prostate cancer
ndrogen receptor
one metastasis angiogenesis
mmunotherapy
adiotherapy
hemotherapy
receptor  blockers,  bone  targeting  and  antiangiogenic  agents,  endothelin  receptor  antagonists,  growth
factor  inhibitors,  novel  radiotherapeutics  and taxanes,  and  immunotherapeutic  approaches.  Results  and
limitations from  clinical  studies  as well  as  future  needs  for improvement  of CRPC  treatments  are  critically
discussed.
© 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY license.
rowth factor receptor inhibitors
. Introduction
Prostate cancer (PCa) is the most frequently diagnosed malig-
ancy in men  in Western countries [1]. While localized PCa can
otentially be cured by surgery or radiation therapy, metastatic
Ca still remains incurable. For locally advanced or widespread
isease, suppressing the tumor growth by hormone ablation ther-
py represents the common therapeutic option [2]. Although initial
herapy mostly results in signiﬁcant long-term remission, develop-
ent of hormone ablation resistance is inevitable, a status named
astration-resistant PCa (CRPC). In most cases, it takes about 12
o 24 months to therapy resistance [3]. At this stage of disease
Abbreviations: AR, androgen receptor; CRPC, castration-resistant prostate can-
er; ET, endothelin; IGF, insulin-like growth factor; OS, overall survival; PCa, prostate
ancer; PDGFR, platelet-derived growth factor receptor; PFS, progression free sur-
ival; PSA, prostate-speciﬁc antigen; RANK-L, RANK ligand; SD, stable disease; TKI,
yrosine kinase inhibitor; VEGF, vascular endothelial growth factor; VEGFR, vascular
ndothelial growth factor receptor.
∗ Corresponding author at: Department of Urology, Division of Experimental Urol-
gy, Anichstrasse 35, 6020 Innsbruck, Austria. Tel.: +43 512 504 24818;
ax: +43 512 504 24817.
E-mail address: helmut.klocker@uki.at (H. Klocker).
960-0760 ©  2013 The Authors. Published by Elsevier Ltd. 
ttp://dx.doi.org/10.1016/j.jsbmb.2013.06.002
Open access under CC BY license.treatment options are very limited. Until recently, the chemother-
apeutic agent docetaxel represented the treatment of choice after
castration resistance emerged, prolonging the mean life span of
patients for 2.9 months [4].
2. New Drugs for castration resistant prostate cancer
The prostate is an androgen-dependent organ; androgen hor-
mones and their executor, the androgen receptor (AR), are central
drivers of PCa development and progression [5–10]. In hormone-
naïve patients, withdrawal of androgen by surgical or chemical
castration or by antiandrogens blocks AR stimulation and results
in massive induction of apoptosis and tumor shrinkage. The vast
majority of tumors initially respond to hormone ablative treatment,
however, almost all tumors also develop resistance to this kind of
therapy, after two to three years leading to further progression of
the disease (disease-monitoring methods are summarized in Fig. 1)
[11–13].
The combined research efforts of the last two decades boosted
the insight into the mechanism of therapy resistance in PCa and
provided the basis for the development of new agents (see Table 1
and Fig. 2 for an overview). The most important ﬁnding was that
in the castration-resistant tumor the AR remains the key regula-
tor and driver of tumor growth, spread and survival and the most
promising therapeutic target [11]. During progression to CRPC,
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Oig. 1. Monitoring of prostate cancer, therapy efﬁcacy and tumor progression. Seve
etermining of disease progression (right panel). The Computer tomography image
ancer.t adapts to the conditions of hormone ablation therapy by sev-
ral mechanisms like gain-of-function mutations, expression of
onstitutively active receptor splice variants, receptor overexpress-
on, alternative activation through signaling cross-talk, a change
able 1
ummary of new drugs for castration resistant prostate cancer.
Agent Target Approved f
Drugs targeting the androgen receptor activity
Abiraterone acetate CYP17 enzyme Yes 
Enzalutamide Androgen receptor Yes 
Oteronel CYP17 enzyme No 
Drugs targeting bone metastasis and environment
Denosumab RANK-L Yes 
Alpharadin Tumor cells in bone No 
Atrasentan Endothelin receptor A No 
Zibitentan Endothelin receptor A No 
Immunotherapy and immunomodulators
Sipuleucel-T APC-antiPAP Yes 
Prostavac APC-antiPSA No 
Ipilumumab CTLA-4 Yes 
Thalidomide NK cells, regulatory T-cells VEGF, bFGF, IL-6, TNF Yes 
Lenalidomide VEGF, bFGF, Interleukin-8, TNF Yes 
Inhibitors of angiogenesis
Bevacizumab VEGF Yes 
Sorafenib VEGFR Yes 
Sunitinib VEGFR Yes 
TRC105 Vascular endothelium No 
Aﬂibercept VEGF Yes 
Growth factor receptor inhibitors
Geﬁtinib EGFR Yes 
Erloninib EGFR Yes 
Lapatinib EGFR, ERBB2 Yes 
Imatinib PDGFR Yes 
Figitumumab IGF1R No 
Cetuximab EGFR Yes 
Cabozantinib cMET, VEGFR2 Yes 
New Taxanes
Carbazitaxel Tumor cell division Yes 
verview on new therapeutic agents for CRPC that have been recently approved or are inthods are used for assessment of PCa spread, monitoring of therapy responses and
panel) show the metastatic sites (white arrows) of patients with advanced prostatein the balance of coactivators and corepressors, recruitment of
adrenal gland hormones or intratumoral de-novo androgen synthe-
sis as alternative androgen hormone sources or downregulation of
androgen metabolizing enzymes [7,12,14–17]. The advancement in
or cancer treatment Study phase prostate cancer References clinical studies
Approved 2011 [18,19]
Approved 2012 [24]
III [35,36]
Approved 2010 [42]
III [43,44]
II [49]
III [53–55]
Approved 2010 [59,60]
III [61]
III [63]
II [57]
I/II [57]
III [70]
III [73]
III [37]
I/II [77]
III [74]
II [79,80]
II/III [38]
II [81,82]
II [84]
II [88,37]
II [90]
III [90]
Approved 2010 [91]
 clinical trials and their mode of action and direct targets.
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Fig. 2. Schematic overview on new therapeutic agents for castration resistant prostate cancer (CRPC) and their targets. In metastatic CRPC testicular androgen supply is blocked
by  androgen deprivation therapy through chemical or surgical castration. Tumor cells (PCa) rely on the supply of weak androgen hormones from the adrenal gland, which are
converted to testosterone and dihydrothestosterone (DHT) through P450 cytochrome 17,20 lyase (CYP17A) and 5-reductase (5Red). The androgen receptor (AR), which
is  often overexpressed and or mutated is activated by hormones, gain of function mutations and crosstalk with growth receptor signaling pathways and transported to the
nucleus where it binds to genomic AR binding sites and initiates formation of a transcription complex and regulates genes expression. Bone is the preferred site of metastasis
of  prostate cancer. Prostate cancer cells release cytokines, protease and regulators to manipulate the cells in their environment (ﬁbroblasts, osteoclasts, osteoblasts), induce
angiogenesis and degrade extracellular matrix compounds (ECM) and release growth factors and compounds supporting tumor cell growth, survival and metabolism. Growth
factors activate their receptors on the surface of the tumor cells to trigger intracellular signaling cascades that enhance metabolism, cell cycle progression and survival signals
either  directly or through stimulation of transcription factors (TF) in the nucleus. Additional players at the metastatic sites are inﬁltrating lymphocytes and other cells of the
immune system, especially cytotoxic T-cells, which attack tumor cells. Symbols: >, stimulation or release; |; inhibition; , therapeutic stimulation; , therapeutic
inhibition.
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nderstanding these molecular mechanisms of therapy resistance
ed to the screening for new drugs to inhibit AR signaling in the
dvanced cancer disease stage [18].
.1. New drugs targeting the androgen receptor
One important mechanism for prostate tumors to overcome the
ut-off from testicular androgen supply is intratumoral androgen
roduction from adrenal gland androgen precursors or de-novo
ynthesis [17]. This mechanism is addressed with androgen syn-
hesis inhibitors. Abiraterone acetate (Zytiga®) is a selective oral
nhibitor of Cytochrome P450 (CYP) 17, a key enzyme in the produc-
ion of androgens, estrogens and glucocorticoids within the adrenal
teroid hormone synthetic pathway. CYP17 inhibition results in a
urther decrease of androgen levels in the circulation and in the
umors of CRPC patients [19]. CYP17 catalyzes two essential reac-
ions in steroid hormone biosynthesis: the 17-alpha-hydroxylase
eaction catalyzes the production of hormone precursors 17OH-
regnenolone and 17OH-progesterone, the C17,20-lyase activity of
YP17 then leads to the production of sex steroid precursors DHEA
nd androstenedione. Abiraterone acetate is a potent and selective
rreversible inhibitor of both enzymatic activities [11]. After uptake,
t is converted to the active compound abiraterone. In the circu-
ation the drug is highly protein bound (>99%). It is metabolized
o inactive metabolites by the cytochrome P450 oxidase CYP3A4
nd the hydroxysteroid sulfotransferase SULT2A1, mainly in the
iver. Tracer studies identiﬁed abiraterone sulfate and N-oxid aber-
terone sulfate as the main inactive metabolites [20,21].
In preclinical studies, Abiraterone acetate has been shown to
nhibit the ACTH-mediated stimulation of adrenal cells followed by
 signiﬁcant dose-dependent decrease in circulating testosterone
evels [22,23]. Therefore continuous CYP17 inhibition induces sec-
ndary hormone ablation responses in CRPC patients. Several
tudies evaluated Abiraterone acetate in chemotherapy-naïve and
n docetaxel-pretreated CRPC patients with response rates from 45
o 75%. The encouraging data from these studies were followed by
 multicenter study evaluating the therapeutic effect of the drug
n combination with prednisone given as a replacement for corti-
ol, whose synthesis is also blocked by Abiraterone acetate. This
tudy reported an overall survival (OS) of 14.8 months in treated
atients compared to an OS of 10.9 months in patients receiving
rednisone alone. Moreover, Abiraterone acetate showed improve-
ents of progression free survival (PFS) of 5.6 vs. 3.6 months and
SA response rates of 29.1 vs. 5.5% compared to prednisone [24].
he drug was generally well tolerated with only mild side effects.
In 2011, Abiraterone acetate (Zytiga®) in combination with
rednisone has ﬁnally been approved for the treatment of patients
ith CRPC who have received prior docetaxel chemotherapy. A
ubsequent study focused on treatment of chemo-naïve patients
COU-AA-302). In these patients, the median radiographic PFS was
6.5 months with Abiraterone acetate-prednisone and 8.3 months
ith prednisone alone. Furthermore, with Abiraterone acetate-
rednisone OS improved and delayed subsequent chemotherapy
nd cancer-related pain [25]. Based on these, data Abiraterone
cetate has been approved for treatment in the pre-chemotherapy
hase of CRPC in 2013.
Besides surgical, LHRH agonist and antagonist inhibition of
estosterone biosynthesis non-steroidal antiandrogens like ﬂu-
amide (Eulexin®) and bicalutamide (Casodex®) which inhibit the
R transactivation function belong to the standard therapeutic
rmamentarium for treatment of advanced PCa and are also used in
ombination with anti-LHRH treatment to achieve complete andro-
en blockade and prevent the initial ﬂare-up phenomenon of LHRH
gonists [4,26]. These antiandrogens have a low afﬁnity for the
R and can lose their AR inhibitory property or even become AR
gonists in castration-resistant tumor cells [27,28]. A reason for & Molecular Biology 138 (2013) 248– 256 251
that may  be the corruption of the AR inhibitory effect by interac-
tion of AR with pioneering transcription factors like FoxA1. FOXA1
binding reorganizes chromatin and makes it more accessible for AR
binding, thus, modulating the AR response [29]. This transcription
factor was  shown to shift the antagonist/agonist balance of bica-
lutamide toward an agonist response [30]. New next-generation
AR antagonists have been developed for use in CRPC patients that
have a higher afﬁnity for the AR with less agonistic potential and
enhanced inhibitory efﬁcacy.
The ﬁrst representative of next-generation antiandrogens to
enter the clinics is Enzalutamide (Xtandi®, MDV3100), a selec-
tive AR antagonist that inhibits AR signaling by preventing nuclear
translocation of the ligand-receptor complex and its transforma-
tion to a transactivation-competent transcription factor, thereby
blocking the AR from regulating its target genes [31]. Results
from early clinical studies showed a substantial antitumor activ-
ity and signiﬁcant PSA decrease under MDV3100 therapy in CRPC
patients with and without previous chemotherapy [32,33]. Two
large phase III clinical studies, AFFIRM and PREVAIL (the latter is
still ongoing), were initiated to test MDV3100 efﬁcacy in patients
who received prior docetaxel therapy and in chemotherapy-naïve
patients, respectively. The ﬁnal outcome of the AFFIRM trial has
been published recently showing that MDV3100 prolonged OS,
slowed disease progression, and improved quality of life in CRPC
post-docetaxel treatment [34]. The median OS was 18.4 months
with MDV3100 compared to 13.6 months in the placebo group, and
the radiographic PFS improved from 2.9 to 8.3 months. This ﬁnding
led to approval of MDV3100 for post chemotherapy treatment by
the FDA.
Orteronel (TAK-700) was originally known as VN/124-1 and
is an oral, selective, reversible, non-steroidal androgen synthesis
inhibitor. It inhibits only one of the two  enzymatic reactions cat-
alyzed by CYP17, the 17,20 lyase activity. Due to its low inhibition
of 17-hydroxylase activity, it has a negligible effect on glucocorti-
coid synthesis and its administration does not require concomitant
cortisol replacement [35]. A recent study quantiﬁed the inhibitory
activity and speciﬁcity of TAK-700 for testicular and adrenal andro-
gen production by evaluating its effects on CYP17A1 enzymatic
activity and showed potent inhibition of 17,20-lyase activity in
monkey adrenal cells and human adrenal tumor cells and reduction
of circulating testosterone levels in monkeys [36]. After successful
phase I and phase II studies to date, two phase III studies evaluating
the effect of TAK-700 in combination with prednisone are ongoing
[37,38].
While the new AR targeting drugs are introduced into clinical
practice, preclinical studies continue to better understand their
molecular function and the development and possible preven-
tion of resistance mechanisms. Despite therapeutic efﬁcacy in the
majority of CRPC patients, it also became clear that primary and
acquired resistance to this drug occurs, mostly accompanied by
increasing PSA levels suggesting resumed AR signaling. Several pos-
sible reasons for this, like up-regulation of CYP17A1, constitutive
gain-of-function mutations of the AR through generation of trun-
cated splice variants or activation of a mutated promiscuous AR by
endogenous or exogenous steroids have been shown but remain
to be elucidated in detail [39]. Moreover, there is as good ratio-
nale to evaluate a combined treatment with substances providing
complementary AR inhibition such as Abiraterone acetate and
Enzalutamide [11,39] or to combine the new drugs with recently
deﬁned inhibitors of constitutively active variant ARs [40].
2.2. Agents targeting bone metastases and environmentBone metastases represent the most common type of metas-
tases in PCa. Therefore the bone represents an important
therapeutic target in advanced stages of PCa. It is a dynamic tissue
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hat undergoes constant remodeling by osteoclasts and osteoblasts.
his environment is the ideal “soil” for tumors such as breast and
rostate [41]. Tumor cells disturb the balance of osteoblast and
steoclast activity by secretion of bone-active regulatory factors
uch as endothelin-1 (ET1), interleukin-6 (IL6) and transforming
rowth factor  (TGF) in order to enhance bone turnover and
elease of nutrients and growth factors. A crucial regulator in bone
hysiology is the RANK ligand (RANK-L). Under physiological con-
itions it is mainly produced by osteoblasts and binds to its receptor
ANK on the surface of monocytes and osteoclasts, thereby, stimu-
ating osteoclast formation, differentiation and activation. RANK-L
s increased in metastatic lesions of prostate cancer resulting in
one destruction or pathological bone formation [42,43].
Denosumab (Xgeva®) is a fully humanized monoclonal antibody
hat speciﬁcally inhibits osteoclast activity by binding to RANK-L,
hereby, modulating intracellular signaling pathways involved in
steoclast formation, their function and survival. In a large phase III
ulticenter study (HALT) comparing Denosumab with bisphospho-
ate zoledronic acid, the standard treatment option for deferring
evelopment and progression of bone metastases in CRPC, the
edian time to bone metastasis was 20.7 months versus 17.1
onths, respectively [44]. In 2010, Denosumab was approved for
reatment of skeletal-related events in solid tumors including PCa.
Takeup of salts for bone mineralization is utilized to guide new
mitters to the bone. Radium-223 chloride (Alpharadin®) is an
njectable form of an alpha particle emitting radium-223 salt seek-
ng bone [45]. First clinical studies reported a reduction in bone
etastasis markers and PSA reduction as well as improved OS after
lpharadin therapy [45]. Currently a phase III double-blind, ran-
omized, multinational study (ALSYMPCA) is comparing treatment
ith Alpharadin vs. placebo in CPRC patients with bone metas-
ases. A recently presented analysis of the study showed improved
S with a highly favorable safety proﬁle. The median OS was  14
onths in the Alpharadin group compared to 11.2 months in the
lacebo group [46].
Endothelins (ETs) are vasoconstricting 21-amino acid peptides
hat also stimulate the release of factors involved in the reg-
lation of bone homeostatis. In particular, ET-1 is released by
rostate tumor cells and plays a crucial role in PCa development
nd progression through induction of cell proliferation, survival,
ngiogenesis and ﬁnally formation of bone metastases [47,48]. The
unction of endothelins is mediated through two  receptors, ET-
 and ET-B. Preclinical studies found that ET receptor levels on
umor cells correlate with tumor stage, tumor grade and metas-
ases. Moreover, endothelin receptor A is also highly expressed in
one osteoblasts and osteoclasts and endothelin stimulates new
one formation and development of osteoblastic bone metastases.
onsequently ET receptors seem promising anticancer targets
47,49,50].
Atrasentan is a selective ET-A antagonist; it blocks ET-A with
 1800-fold higher selectivity than ET-B. In a phase II study per-
ormed in CRPC patients, Atrasentan prolonged the time to disease
rogression and PSA progression signiﬁcantly in comparison to the
lacebo [51]. However, in a subsequent phase III study involving
09 patients, Atrasentan failed to reduce the risk of disease pro-
ression. Nevertheless, quality of life and pain scores as well as
lkaline phosphatase (AP) and PSA levels improved [52]. Recently,
he SWOG S0421 phase III study comparing docetaxel plus pred-
isone vs. the addition of Atrasentan to these drugs was  stopped
y the Data and Safety Monitoring Committee because neither OS
or PFS were signiﬁcantly improved [38].
Zibotentan (ZD4054) is another highly selective ET-A antagonist.
lthough it could not show improvement of disease progression
n comparison to the placebo, OS was signiﬁcantly longer in the
ibotentan arm in an initial safety and efﬁcacy study [53,54]. In
hase III studies, Zibotentan did not show a signiﬁcant beneﬁt in & Molecular Biology 138 (2013) 248– 256
CRPC patients or in patients with biochemical progression [55,56].
Still under way  are studies comparing Doxetacel treatment with
or without addition of Zibotentan [38]. A preliminary analysis of a
small tolerability and efﬁcacy study showed some beneﬁt for this
combination [57].
2.3. Immunotherapy and immunomodulators
The concept of training the immune system to overcome tumor-
induced tolerance using vaccinations against tumor antigens is
successfully used in the treatment of several cancer entities.
Immunotherapeutic approaches aim to modulate immunostimu-
latory pathways that help to maintain and to prolong the activity
of antigen-presenting cells and enhance cytotoxic T-cell-mediated
tumor regression [58,59]. Recent evidence suggests that PCa is more
immunogenic than previously thought [59,60]. Thus, a number of
immunological anticancer strategies are currently under investiga-
tion.
Sipuleucel-T (Provenge®) is an autologous vaccine consisting
of patients’ autologous peripheral blood mononuclear cells stimu-
lated ex vivo to generate antigen-presenting cells. The recombinant
stimulatory protein used consists of the target antigen prostatic
acid phosphatase (PAP) fused to granulocyte macrophage colony
stimulating factor (GM-CSF). After reinfusion of the stimulated
autologous antigen presenting cells into the patient an immune
response to PAP-expressing PCa cells is induced. Sipuleucel-T is
administered to patients as a freshly manufactured preparation
by intravenous injection. Standard treatment consists of three
infusions [61]. Although in a phase III study, the median time to pro-
gression of PCa patients under Sipuleucel-T therapy did not differ
from placebo-treated patients, the OS was  in favor of those patients
with immunotherapy (25.8 months vs. 21.7 months) [61,62]. In
2010, Sipuleucel-T was  approved by the FDA for the treatment
of asymptomatic or minimally symptomatic CRPC. The limited
availability especially outside the US and the high therapy costs
currently restrict Sipuleucel-T as a standard treatment option for
CRPC.
Prostvac-VF is a recombinant vaccinia-based viral construct
encoding PSA and three immune co-stimulatory molecules
(intracellular adhesion molecule-1, B7-1 and leukocyte function-
associated antigen-3) [63]. In a randomized phase II study involving
125 patients with minimally symptomatic CRPC, the median PFS
(the primary endpoint) was  similar in the group receiving Prostvac-
VF to that in the group receiving control vectors. At three years
post-study, the median survival in the Prostvac-VF group was
signiﬁcantly longer (21.5 vs. 16.6 months for controls) with an esti-
mated HR of 0.56 (95% CI 0.37, 0.85; p = 0.061) [62]. A phase III study
is currently ongoing [38].
Another immune-modulating approach is the blockade of
cytotoxic T-lymphocyte-assiociated antigen 4 (CTLA-4) using the
monoclonal humanized antibody Ipilimumab (MDX-101, Yervoy®),
which was approved in 2011 for the treatment of late stage-
melanoma [64]. The antibody target CTLA-4 is a co-stimulatory
molecule that binds to CD80 (B7) on the surface of T-lymphocytes
and functions as a negative regulator of T-cell activation as part of
the system regulating an immune response. Trapping of CTLA4 by
Ipilimumab enhances the cytotoxic T cell response against tumor
cells [65]. Recently a phase III study in chemo-naive PCa (CA184-
095) and another phase III study in docetaxel-pretreated patients
have been started (CA184-043) [38]. In addition, approaches to
combine Ipulimumab stimulation of an immune response with vac-
cination is a promising approach tested for the treatment of CRPC
and other tumors [65].
Thalidomide and its second-generation analog Lenalidomide
are immunomodulatory and antiangiogenic compounds target-
ing both cancer cells and their microenvironment. While their
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ntiangiogenic activity is due to inhibition of the secretion of VEGF,
FGF, Interleukin-8 or TNF and ﬁbroblast growth factor (FGF) from
umor and tumor stroma cells, their immunomodulatory effect is
aused by stimulation of T-cells and natural killer cells as well as
he inhibition of T-regulatory cells [59].
In phase II studies, Thalidomide treatment in combination with
ocetaxel chemotherapy showed a decline of serum PSA values,
nd an improvement of OS and PFS. Treatment with combinations
f Docetaxel plus Thalidomide plus Bevacizumab (an antiangio-
enetic monoclonal antibody, see the next chapter) even showed
SA responses in 80% of the patients [66]. However, Thalidomide
reatment was accompanied by toxic side effects including deep
enous thrombosis, constipation or neuropathies.
To reduce the side effects of these therapies, a second-
eneration analog named Lenalidomide with a more favorable
eurotoxic proﬁle has been developed. In a phase I/II study,
enalidomide monotherapy showed stable disease in 63% and
SA responses in 38% of CRPC patients. Combination therapy
f Lenalidomide plus Docetaxel caused PSA declines of >50% in
alf of the treated patients [67]. To date, several studies inves-
igating Lenalidomide in combination with chemotherapy, with
M-CFS or with Cyclophosphamide are ongoing [38]. The com-
ined therapy with Lenalidomide and Bevacizumab plus Doxetacel
nd prednisone was associated with high PSA (85.2%) and tumor
86.7%) responses in metastatic CRPC, with manageable toxicities
65,68].
.4. Inhibitors of angiogenesis
Tumor growth beyond a size of 3 mm is dependent on the
evelopment of new blood vessels, a process called angiogenesis
69]. One of the key players during angiogenesis is the vascular
ndothelial growth factor A (VEGF-A), which signals through VEGF
eceptors (VEGFR) [70]. Tumor cells enhance local VEGF produc-
ion to stimulate the outgrowth of new blood vessels; moreover
levated VEGFR levels are associated with cancer progression and
oor survival rates. Thus, targeting the VEGF pathway represents an
ttractive anti-cancer approach. Several approaches are employed
o inhibit the VEGF pathway either by targeting VEGF itself, or the
EGF receptors or by targeting downstream signals in the pathway
70].
Bevacizumab (Avastin®) is a monoclonal antibody that potently
nhibits VEGFR signaling through binding and neutralizing VEGF-A.
urrently Bevacizumab is approved for the treatment of sev-
ral cancer entities including colorectal cancer or breast cancer.
lthough phase II studies in PCa, where Bevacizumab has been
dministered in combination with chemotherapy, showed encour-
ging results, Bevacizumab has not been successful in a phase III
etting [71]. The combination with docetaxel and prednisone did
ot result in any OS beneﬁt in comparison to docetaxel and pred-
isone alone. Moreover, addition of Bevacizumab was associated
ith higher treament-related toxicity and with an increased num-
er of treatment-related deaths [72].
Sorafenib (Nexavar®) is a multi-tyrosine kinase inhibitor that
ecreases tumor growth and disrupts tumor microvasculature
hrough inhibition of multiple targets including the VGEF receptors
EGFR-1, VEGFR-2 and VEGFR-3 as well as Raf serine/threonine
inases and platelet-derived growth factor receptor  (PDGFR)
73]. Thus, besides angiogenesis Sorafenib also targets growth fac-
or pathways. Currently, Sorafenib is clinically approved for the
reatment of several cancer entities like renal or hepatocellular
ancer [73]. Phase II studies in CRPC observed therapeutic activ-
ties of Sorafenib, such as prevention of radiologic progression
nd regression of bone metastases. However, no PSA decline was
bserved under Sorafenib therapy. Therefore the investigators of
hese studies concluded that PSA measurement might not be an & Molecular Biology 138 (2013) 248– 256 253
accurate marker of therapy response under Sorafenib treatment
[74]. Another phase II study of sorafenib in combination with bica-
lutamide in patients with chemotherapy-naive CRPC reported a PSA
response or stable disease for 6 months or longer in 47% of the
patients. Serum PSA declines of ≥50% occurred in 32% of patients.
The median time to treatment failure was 5.5 months [75]. Cur-
rently, Sorafenib monotherapy is evaluated in a phase III study of
patients in docetaxel-refractory PCa patients [38].
Aﬂibercept (Eylea®) is an anti-VEGF agent representing a VEGF-
trap. It is a recombinant protein consisting of the Fc portion
of human IgG1 combined with the extracellular ligand-binding
domains 2 and 3 of the human VEGFR 1 and 2 which functions as a
decoy receptor for VEGFs [76]. Aﬂibercept is currently under inves-
tigation in phase III (VENICE trial) in combination with ﬁrst-line
docetaxel, treatment [38].
Another multi-tyrosine kinase inhibitor is Sunitinib (Sutent®)
which inhibits the tyrosine kinase receptors VEGFR, platelet
derived growth factor receptors (PDGFR) and c-kit. Sunitinib is
approved for treatment of renal cell cancer, gastrointestinal stromal
tumors or pancreatic neuroendorine tumors [77]. Zurita et al. ana-
lyzed Sunitinib plus prednisone and doxetacel in CRPC patients in a
phase I/II study and found that the combination of all three agents
is well tolerated and has substantial beneﬁts regarding response
rates and OS beneﬁts [78]. However, a phase III study investigating
sunitinib plus prednisone in patients with metastatic CRPC after
failure of docetaxel chemotherapy (SUN 1120) with OS as the pri-
mary endpoint was prematurely discontinued recently due to lack
of efﬁcacy [38].
A protein that is essential for angiogenesis and vessel develop-
ment and, thus, a promising anti-vascular target is Endoglin/CD105
[79]. It is a major glycoprotein of the vascular endothelium forming
a homodimeric transmembrane complex that binds TGF-1 and
-3 with high afﬁnity. It participates in transforming growth fac-
tor beta receptor signaling. An anti-endoglin monoclonal antibody
(TRC105) was tested in a variety of solid tumors. Ongoing clini-
cal trials are testing it in combination with chemotherapy or VEGF
inhibitors or as a single agent in prostate, ovarian, bladder, breast,
and hepatocellular cancer [80].
2.5. Growth factor receptor inhibitors
Growth factors stimulate proliferation, support survival and
enhance migration and invasion of prostate cancer cells [49].
Growth factors bind to and activate protein tyrosine kinase recep-
tors on the cell surface, which trigger the intracellular signaling
systems [49]. These signaling cascades are major drivers of carcino-
genesis, tumor progression, metastatic spread and development
of resistance to tumor therapies and are of particular interest as
therapeutic targets. In PCa, epidermal-, ﬁbroblast-, PDGF-, and IGF-
systems were reported deregulated either at the growth factor or
the receptor levels or both. New molecular therapeutics have been
developed for inhibition of the peptide growth factors themselves,
or for blocking their receptors or intracellular signaling compo-
nents or inhibiting the tyrosine kinase activity of growth factor
receptors. They have been tested in different tumor identities either
alone or in different combination therapies. With regard to prostate
cancer, the therapeutic effects achieved in clinical trials have been
modest so far.
Epidermal growth factor receptor (EGFR) targeting agents are
successfully used in different cancer entities like lung or breast can-
cer. In PCa, Geﬁtinib (Iressa®) an EGFR tyrosine kinase inhibitor
(TKI), however, failed to demonstrate PSA declines or clinical
responses when given as a monotherapy in CRPC patients [81,82].
Likewise, combination therapies of Geﬁninib and Docetaxel did
not improve OS or PFS. The EGFR TKI Erlotinib (Tarceva®) exerted
a moderate activity in chemotherapy-naive, CRPC patients, with
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ome patients showing a PSA response [38]. Currently the EGFR
nd ERBB2 (HER-2) dual TKI Lapatinib (Tyverb®) is under clinical
nvestigation. Phase II studies so far indicate that it may  have some
fﬁcacy in men  with CRPC although only few PSA responses were
bserved [83,84].
The chimeric monoclonal antibody Cetuximab (IMC-A12,
rbitux®) binds to EGFR and prevents its intracellular signaling.
urrently, it is approved for treatment of wild-type KRAS colon
nd head and neck cancer. The combination of cetuximab with
itoxantrone plus prednisone was evaluated in post-docetaxel
herapy CRPC patients in a phase II study including 115 patients.
he observed effects did not support the use of cetuximab in this
rug combination, but it might still be of use in other settings
85].
The TKI Imatinib (Gleevec®) was developed for targeting the
usion kinase Bcl-Abl, which plays a central role in leukemia. It also
nhibits the kinase activities of other receptors like c-Kit, the recep-
or for hepatocyte growth factor, or PDGF receptor [49]. Imatinib
onotherapy studies and small combination studies with doce-
axel or the antiangiogenic drug Sorafenib in PCa patients are
isappointing so far [86].
Inhibitors of the insulin-like growth factor receptor-1 (IGF1R)
re studied in a number of different tumor types including PCa
87–89]. Administration of the anti-IGFR1 monoclonal antibody
igitumumab (CP-751,871) a fully humanized IgG2 monoclonal
ntibody in combination with docetaxel showed radiographic
esponses in 22% and SD for more than 6 months in 11%
f CRPC patients [90]. Further clinical studies are under way
38].
Cabozantinib (XL184, CometriqTM) is an oral small molecule
nhibitor of multiple kinase signaling pathways including c-MET
nd VEGFR2. In phase I clinical studies, Cabozantinib resulted in
umor regression in multiple cancer types [91]. A recently pub-
ished phase II study compared response rates at 12 weeks and PFS
fter random assignment of either Cabozantinib or placebo. Median
FS was 23.9 weeks in the treatment and 5.9 weeks in the placebo
roup [92]. Cabozantinib treatment resulted in stable disease in 75%
nd objectives response rates in 5% of treated patients. A phase III,
andomized, double-blind, controlled study of Cabozantinib versus
rednisone in metastatic CRPC patients who have received prior
ocetaxel and Abiraterone acetate or MDV3100 is under way. A sec-
nd phase III study is comparing Cabozantinib versus Mitoxantrone
lus prednisone in men  with previously treated symptomatic CRPC
38].
.6. New taxanes
Cabazitaxel (Jevtana®) is a novel taxane that showed activity in
ocetaxel-resistant tumor cell lines [93]. Recently, cabazitaxel was
eported to have an OS beneﬁt in patients with CRPC who have
rogressed in docetaxel therapy when compared to mitoxantrone
hemotherapy (TROPIC trial) [93]. Median progression-free sur-
ival was 2.8 months in the cabazitaxel group and 1.4 months in
he mitoxantrone group. Like other taxanes, cabazitaxel exerts its
ytotoxic effect through mitotic arrest at the metaphase-anaphase
ransition, ultimately leading to cell death. Unlike docetaxel that
as an afﬁnity for multidrug resistance (MDR) proteins, which
s as a major mechanism of resistance, cabazitaxel demonstrated
oor recognition by MDR  proteins [93]. On the basis of this ﬁnd-
ng, cabazitaxel is indicated for the treatment of patients with
etastatic CRPC who have previously been treated with doce-axel. In 2010, Cabazitaxel was approved by the FDA. Even through
oxicity is still a matter of concern, a recent safety report based
n 111 treated patients concluded that side effects are tolerable
94].
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3. Conclusion
In the last few years, many different therapeutic strategies for
CRPC have been developed and evaluated in clinical studies. Sev-
eral strategies showed objective clinical beneﬁt and have been
approved for clinical use. On the other hand, there are several
examples of new molecular targeting drugs that showed promising
results in preclinical PCa models but showed insufﬁcient effects in
clinical phase III studies. This raises the question of how preclin-
ical models and preclinical testing can be improved to avoid such
failures in the future.
The expanded arsenal of drugs now available for treatment of
CRPC denotes a big step forward to tailor treatment for each patient
and to prolong control of the disease. The newly approved drugs
can retard disease progression by several months but still cannot
prevent it. Further efforts are necessary to optimize the sequence
of use and the best combinations of the different drugs in order to
optimize and further enhance PFS and OS survival and quality of life
of affected patients. Many of the newly available molecular thera-
peutics in the pipeline still have to prove their efﬁcacy in clinical
praxis. Another challenge is establishment of selection criteria to
deﬁne those patients who are likely to respond to a certain type of
therapy. This means there is also a need for appropriate biomarkers
and companion diagnostics to deﬁne patient populations that will
beneﬁt from speciﬁc treatments.
Acknowledgements
The authors would like to acknowledge the Austrian Research
Fund (FWF, project W0110-B2), the Austrian Cancer Foundation
Tyrol, the Oncotyrol Center for Personalized Cancer Medicine
within the scope of the Austrian COMET program through BMVIT,
BMWFJ  and the Standortagentur Tirol (projects 3.1, II.1.4 and
II.3.3), and the Autonomous Province of Bolzano-South Tyrol (Grant
37/40.3) for funding.
References
[1] A. Heidenreich, J. Bellmunt, M.  Bolla, S. Joniau, M.  Mason, V. Matveev, N. Mottet,
H.P.  Schmid, K.T. van der, T. Wiegel, F. Zattoni, EAU guidelines on prostate can-
cer. Part I: screening, diagnosis, and treatment of clinically localised disease,
Actas Urológicas Espan˜olas 35 (2011) 501–514.
[2] H. Beltran, T.M. Beer, M.A. Carducci, J. de Bono, M.  Gleave, M.  Hussain, W.K. Kelly,
F.  Saad, C. Sternberg, S.T. Tagawa, I.F. Tannock, New therapies for castration-
resistant prostate cancer: efﬁcacy and safety, European Urology 60 (2011)
279–290.
[3] V. Pagliarulo, S. Bracarda, M.A. Eisenberger, N. Mottet, F.H. Schroder, C.N.
Sternberg, U.E. Studer, Contemporary role of androgen deprivation therapy for
prostate cancer, European Urology 61 (2012) 11–25.
[4] N. Mottet, J. Bellmunt, M.  Bolla, S. Joniau, M.  Mason, V. Matveev, H.P. Schmid, K.T.
van der, T. Wiegel, F. Zattoni, A. Heidenreich, EAU guidelines on prostate can-
cer. Part II: treatment of advanced, relapsing, and castration-resistant prostate
cancer, European Urology 59 (2011) 572–583.
[5] Z. Culig, H. Klocker, G. Bartsch, A. Hobisch, Androgen receptors in prostate
cancer, Endocrine-Related Cancer 9 (2002) 155–170.
[6] Z. Culig, H. Klocker, G. Bartsch, A. Hobisch, Androgen receptor mutations in
carcinoma of the prostate: signiﬁcance for endocrine therapy, American Journal
of  Pharmacogenomics 1 (2001) 241–249.
[7] I.E. Eder, Z. Culig, T. Putz, C. Nessler-Menardi, G. Bartsch, H.  Klocker, Molecular
biology of the androgen receptor: from molecular understanding to the clinic,
European Urology 40 (2001) 241–251.
[8] C. Huggins, C.V. Hodges, Studies on prostatic cancer. I. The effect of castra-
tion,  of estrogen and androgen injection on serum phosphatases in metastatic
carcinoma of the prostate, CA Cancer Journal for Clinics 22 (1972) 232–240.
[9] D. Wang, D.J. Tindall, Androgen action during prostate carcinogenesis, Methods
in  Molecular Biology 776 (2011) 25–44.
10] S.M. Green, E.A. Mostaghel, P.S. Nelson, Androgen action and metabolism in
prostate cancer, Molecular and Cellular Endocrinology 360 (2012) 3–13.
11] R. Ferraldeschi, C. Pezaro, V. Karavasilis, J. de Bono, Abiraterone and novel
antiandrogens overcoming castration resistance in prostate cancer, Annual
Review of Medicine 64 (2012) 1–13.
12] J.L. Mohler, C.W. Gregory, O.H. Ford III, D. Kim, C.M. Weaver, P. Petrusz, E.M.
Wilson, F.S. French, The androgen axis in recurrent prostate cancer, Clinical
Cancer Research 10 (2004) 440–448.
mistry
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[I. Heidegger et al. / Journal of Steroid Bioche
13] G. Attard, C.S. Cooper, J.S. De Bono, Steroid hormone receptors in prostate can-
cer:  a hard habit to break? Cancer Cell 16 (2009) 458–462.
14] N. Mitsiades, C.C. Sung, N. Schultz, D.C. Danila, B. He, V.K. Eedunuri, M.  Fleisher,
C.  Sander, C.L. Sawyers, H.I. Scher, Distinct patterns of dysregulated expres-
sion of enzymes involved in androgen synthesis and metabolism in metastatic
prostate cancer tumors, Cancer Research 72 (2012) 6142–6152.
15] N. Nadiminty, A.C. Gao, Mechanisms of persistent activation of the androgen
receptor in CRPC: recent advances and future perspectives, World Journal of
Urology 30 (2012) 287–295.
16] S. Haile, M.D. Sadar, Androgen receptor and its splice variants in prostate cancer,
Cellular and Molecular Life Sciences 68 (2011) 3971–3981.
17] K.K. Waltering, A. Urbanucci, T. Visakorpi, Androgen receptor (AR) aberrations
in  castration-resistant prostate cancer, Molecular and Cellular Endocrinology
360 (2012) 38–43.
18] G. Attard, J.S. De Bono, Translating scientiﬁc advancement into clinical beneﬁt
for  castration-resistant prostate cancer patients, Clinical Cancer Research 17
(2011) 3867–3875.
19] A.H. Reid, G. Attard, E. Barrie, J.S. De Bono, CYP17 inhibition as a hormonal
strategy for prostate cancer, Nature Clinical Practice Urology 5 (2008) 610–620.
20] M.  Acharya, M.  Gonzalez, G. Mannens, R. De Vries, C. Lopez, T. Grifﬁn, N. Tran, A
phase I, open-label, single-dose, mass balance study of 14C-labeled abiraterone
acetate in healthy male subjects, Xenobiotica 43 (2013) 379–389.
21] Zytiga prescibe information, Ref Type Magazine Article (2013) www.zytiga.com
22] S.E. Barrie, G.A. Potter, P.M. Goddard, B.P. Haynes, M. Dowsett, M.  Jarman,
Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17
alpha-hydroxylase/C17-20 lyase), Journal of Steroid Biochemistry and Molec-
ular Biology 50 (1994) 267–273.
23] G. Turitto, M.  Di Bisceglie, L. Moraca, N. Sasso, C. Sepede, A. Suriano, S. Romito,
Abiraterone acetate: a novel therapeutic option in hormone-refractory prostate
cancer, Recenti Progressi in Medicina 103 (2012) 74–78.
24] J.S. De Bono, C.J. Logothetis, A. Molina, K. Fizazi, S. North, L. Chu, K.N. Chi,
R.J. Jones, O.B. Goodman, F. Saad Jr., J.N. Staffurth, P. Mainwaring, S. Harland,
T.W. Flaig, T.E. Hutson, T. Cheng, H. Patterson, J.D. Hainsworth, C.J. Ryan, C.N.
Sternberg, S.L. Ellard, A. Flechon, M.  Saleh, M.  Scholz, E. Efstathiou, A. Zivi, D.
Bianchini, Y. Loriot, N. Chieffo, T. Kheoh, C.M. Haqq, H.I. Scher, Abiraterone
and  increased survival in metastatic prostate cancer, New England Journal of
Medicine 364 (2011) 1995–2005.
25] C.J. Ryan, M.R. Smith, J.S. De Bono, A. Molina, C.J. Logothetis, P. de Souza, K. Fizazi,
P.  Mainwaring, J.M. Piulats, S. Ng, J. Carles, P.F. Mulders, E. Basch, E.J. Small, F.
Saad, D. Schrijvers, H. Van Poppel, S.D. Mukherjee, H. Suttmann, W.R. Gerritsen,
T.W.  Flaig, D.J. George, E.Y. Yu, E. Efstathiou, A. Pantuck, E. Winquist, C.S. Higano,
M.E. Taplin, Y. Park, T. Kheoh, T. Grifﬁn, H.I. Scher, D.E. Rathkopf, Abiraterone
in metastatic prostate cancer without previous chemotherapy, New England
Journal of Medicine 368 (2013) 138–148.
26] P. Ferrari, G. Castagnetti, G. Ferrari, B. Baisi, A. Dotti, Combination treatment
versus LHRH alone in advanced prostatic cancer, Urologia Internationalis 56
(Suppl. 1) (1996) 13–17.
27] Y.K. Lau, M.K. Chadha, A. Litwin, D.L. Trump, A dramatic, objective antiandro-
gen withdrawal response: case report and review of the literature, Journal of
Hematology & Oncology 1 (2008) 21.
28] C.E. Bohl, W.  Gao, D.D. Miller, C.E. Bell, J.T. Dalton, Structural basis for antag-
onism and resistance of bicalutamide in prostate cancer, Proceedings of the
National Academy of Sciences of the United States of America 102 (2005)
6201–6206.
29] B. Sahu, M.  Laakso, K. Ovaska, T. Mirtti, J. Lundin, A. Rannikko, A. Sankila, J.P.
Turunen, M.  Lundin, J. Konsti, T. Vesterinen, S. Nordling, O. Kallioniemi, S.
Hautaniemi, O.A. Janne, Dual role of FoxA1 in androgen receptor binding to
chromatin, androgen signalling and prostate cancer, EMBO Journal 30 (2011)
3962–3976.
30] S. Belikov, C. Oberg, T. Jaaskelainen, V. Rahkama, J.J. Palvimo, O. Wrange, FoxA1
corrupts the antiandrogenic effect of bicalutamide but only weakly attenuates
the effect of MDV3100 (Enzalutamide), Molecular and Cellular Endocrinology
365 (2013) 95–107.
31] C. Tran, S. Ouk, N.J. Clegg, Y. Chen, P.A. Watson, V. Arora, J. Wongvipat, P.M.
Smith-Jones, D. Yoo, A. Kwon, T. Wasielewska, D. Welsbie, C.D. Chen, C.S.
Higano, T.M. Beer, D.T. Hung, H.I. Scher, M.E. Jung, C.L. Sawyers, Development of
a  second-generation antiandrogen for treatment of advanced prostate cancer,
Science 324 (2009) 787–790.
32] D. Mukherji, C.J. Pezaro, J.S. De Bono, MDV3100 for the treatment of prostate
cancer, Expert Opinion on Investigational Drugs 21 (2012) 227–233.
33] H.I. Scher, T.M. Beer, C.S. Higano, A. Anand, M.E. Taplin, E. Efstathiou, D.
Rathkopf, J. Shelkey, E.Y. Yu, J. Alumkal, D. Hung, M.  Hirmand, L. Seely, M.J.
Morris, D.C. Danila, J. Humm,  S. Larson, M.  Fleisher, C.L. Sawyers, Antitumour
activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study,
Lancet 375 (2010) 1437–1446.
34] H.I. Scher, K. Fizazi, F. Saad, M.E. Taplin, C.N. Sternberg, K. Miller, R. de Wit, P.
Mulders, K.N. Chi, N.D. Shore, A.J. Armstrong, T.W. Flaig, A. Flechon, P. Main-
waring, M.  Fleming, J.D. Hainsworth, M.  Hirmand, B. Selby, L. Seely, J.S. De Bono,
Increased survival with enzalutamide in prostate cancer after chemotherapy,
New England Journal of Medicine 367 (2012) 1187–1197.
35] C.J. Ryan, D.J. Tindall, Androgen receptor rediscovered: the new biology and
targeting the androgen receptor therapeutically, Journal of Clinical Oncology
29  (2011) 3651–3658.
36] M.  Yamaoka, T. Hara, T. Hitaka, T. Kaku, T. Takeuchi, J. Takahashi, S. Asahi, H.
Miki, A. Tasaka, M.  Kusaka, Orteronel (TAK-700), a novel non-steroidal 17,20-
lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells
[ & Molecular Biology 138 (2013) 248– 256 255
and serum steroid levels in cynomolgus monkeys, Journal of Steroid Biochem-
istry and Molecular Biology 129 (2012) 115–128.
37] K.D. Courtney, M.E. Taplin, The evolving paradigm of second-line hormonal
therapy options for castration-resistant prostate cancer, Current Opinion in
Oncology 24 (2012) 272–277.
38] Clinical trials, www.clinicaltrials.gov, 2013.
39] Y. Li, S.C. Chan, L.J. Brand, T.H. Hwang, K.A. Silverstein, S.M. Dehm, Androgen
receptor splice variants mediate enzalutamide resistance in castration-
resistant prostate cancer cell lines, Cancer Research 73 (2013) 483–489.
40] Y.C. Yang, L.G. Meimetis, A.H. Tien, N.R. Mawji, G. Carr, J. Wang, R.J. Andersen,
M.D. Sadar, Spongian diterpenoids inhibit androgen receptor activity, Molecu-
lar Cancer Therapeutics 12 (2013) 621–631.
41] S. Fili, M. Karalaki, B. Schaller, Mechanism of bone metastasis: the role of osteo-
protegerin and of the host–tissue microenvironment-related survival factors,
Cancer Letters 283 (2009) 10–19.
42] H.L. Neville-Webbe, R.E. Coleman, Bisphosphonates and RANK ligand inhibitors
for the treatment and prevention of metastatic bone disease, European Journal
of Cancer 46 (2010) 1211–1222.
43] J. Sturge, M.P. Caley, J. Waxman, Bone metastasis in prostate cancer:
emerging therapeutic strategies, Nature Reviews Clinical Oncology 8 (2011)
357–368.
44] K. Fizazi, M.  Carducci, M.  Smith, R. Damiao, J. Brown, L. Karsh, P. Milecki, N.
Shore, M. Rader, H. Wang, Q. Jiang, S. Tadros, R. Dansey, C. Goessl, Denosumab
versus zoledronic acid for treatment of bone metastases in men  with castration-
resistant prostate cancer: a randomised, double-blind study, Lancet 377 (2011)
813–822.
45] S. Nilsson, L. Franzen, C. Parker, C. Tyrrell, R. Blom, J. Tennvall, B. Lennernas,
U. Petersson, D.C. Johannessen, M.  Sokal, K. Pigott, J. Yachnin, M.  Garkavij, P.
Strang, J. Harmenberg, B. Bolstad, O.S. Bruland, Bone-targeted radium-223 in
symptomatic, hormone-refractory prostate cancer: a randomised, multicentre,
placebo-controlled phase II study, Lancet Oncology 8 (2007) 587–594.
46] R.M. Macklis, A.O. Sartor, New mechanistic insights into possible radiobiologic
and  pathophysiologic explanations for unexpectedly impressive outcomes data
observed for hormone-refractary metastatic prostate cancer patients treated
with radium 223, Journal of Clinical Oncology 30 (2012) (suppl; abstr 10623),
Ref Type: Abstract.
47] R. Montironi, M.  Scarpelli, A. Lopez-Beltran, L. Cheng, Editorial comment on:
expression of the endothelin axis in noninvasive and superﬁcially invasive
bladder cancer: relation to clinicopathologic and molecular prognostic param-
eters, European Urology 56 (2009) 846–847.
48] J.B. Nelson, S.H. Nguyen, J.R. Wu-Wong, T.J. Opgenorth, D.B. Dixon, L.W. Chung,
N. Inoue, New bone formation in an osteoblastic tumor model is increased by
endothelin-1 overexpression and decreased by endothelin A receptor blockade,
Urology 53 (1999) 1063–1069.
49] C. Nabhan, B. Parsons, E.Z. Touloukian, W.M.  Stadler, Novel approaches and
future directions in castration-resistant prostate cancer, Annals of Oncology
22 (2011) 1948–1957.
50] E.S. Kopetz, J.B. Nelson, M.A. Carducci, Endothelin-1 as a target for thera-
peutic intervention in prostate cancer, Investigational New Drugs 20 (2002)
173–182.
51] M.A. Carducci, R.J. Padley, J. Breul, N.J. Vogelzang, B.A. Zonnenberg, D.D. Daliani,
C.C. Schulman, A.A. Nabulsi, R.A. Humerickhouse, M.A. Weinberg, J.L. Schmitt,
J.B.  Nelson, Effect of endothelin-A receptor blockade with atrasentan on tumor
progression in men  with hormone-refractory prostate cancer: a random-
ized, phase II, placebo-controlled trial, Journal of Clinical Oncology 21 (2003)
679–689.
52] M.A. Carducci, F. Saad, P.A. Abrahamsson, D.P. Dearnaley, C.C. Schulman, S.A.
North, D.J. Sleep, J.D. Isaacson, J.B. Nelson, A phase 3 randomized controlled
trial of the efﬁcacy and safety of atrasentan in men with metastatic hormone-
refractory prostate cancer, Cancer 110 (2007) 1959–1966.
53] N.D. James, A. Caty, M.  Borre, B.A. Zonnenberg, P. Beuzeboc, T. Morris, D.
Phung, N.A. Dawson, Safety and efﬁcacy of the speciﬁc endothelin-A recep-
tor antagonist ZD4054 in patients with hormone-resistant prostate cancer and
bone metastases who were pain free or mildly symptomatic: a double-blind,
placebo-controlled, randomised, phase 2 trial, European Urology 55 (2009)
1112–1123.
54] N.D. James, A. Caty, H. Payne, M. Borre, B.A. Zonnenberg, P. Beuzeboc, S. McIn-
tosh, T. Morris, D. Phung, N.A. Dawson, Final safety and efﬁcacy analysis of the
speciﬁc endothelin A receptor antagonist zibotentan (ZD4054) in patients with
metastatic castration-resistant prostate cancer and bone metastases who were
pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled,
randomized phase II trial, BJU International 106 (2010) 966–973.
55] J.B. Nelson, K. Fizazi, K. Miller, C. Higano, J.W. Moul, H. Akaza, T. Morris, S. McIn-
tosh, K. Pemberton, M.  Gleave, Phase 3, randomized, placebo-controlled study
of  zibotentan (ZD4054) in patients with castration-resistant prostate cancer
metastatic to bone, Cancer 118 (2012) 5709–5718.
56] K. Miller, J.W. Moul, M.  Gleave, K. Fizazi, J.B. Nelson, T. Morris, F.E. Nathan, S.
McIntosh, K. Pemberton, C.S. Higano, Phase III, randomized, placebo-controlled
study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic
castration-resistant prostate cancer, Prostate Cancer and Prostatic Diseases 16
(2013) 187–192.57] D.L. Trump, H. Payne, K. Miller, J.S. de Bono, J. Stephenson, H.A. Burris III, F.
Nathan III, M. Taboada, T. Morris, A. Hubner, Preliminary study of the speciﬁc
endothelin a receptor antagonist zibotentan in combination with docetaxel
in  patients with metastatic castration-resistant prostate cancer, Prostate 71
(2011) 1264–1275.
2 mistry
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[56 I. Heidegger et al. / Journal of Steroid Bioche
58] G. Zhou, H. Levitsky, Towards curative cancer immunotherapy: overcoming
posttherapy tumor escape, Clinical and Developmental Immunology 2012
(2012) 124187.
59] L. Fong, E.J. Small, Immunotherapy for prostate cancer, Current Urology Reports
7  (2006) 239–246.
60] E. Cha, L. Fong, Immunotherapy for prostate cancer: biology and therapeutic
approaches, Journal of Clinical Oncology 29 (2011) 3677–3685.
61] E.J. Small, P.F. Schellhammer, C.S. Higano, C.H. Redfern, J.J. Nemunaitis, F.H. Val-
one, S.S. Verjee, L.A. Jones, R.M. Hershberg, Placebo-controlled phase III trial of
immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic,
asymptomatic hormone refractory prostate cancer, Journal of Clinical Oncology
24  (2006) 3089–3094.
62] P.W. Kantoff, T.J. Schuetz, B.A. Blumenstein, L.M. Glode, D.L. Bilhartz, M.  Wyand,
K.  Manson, D.L. Panicali, R. Laus, J. Schlom, W.L. Dahut, P.M. Arlen, J.L. Gulley,
W.R. Godfrey, Overall survival analysis of a phase II randomized controlled
trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-
resistant prostate cancer, Journal of Clinical Oncology 28 (2010) 1099–1105.
63] R.S. DiPaola, M.  Plante, H. Kaufman, D.P. Petrylak, R. Israeli, E. Lattime, K.
Manson, T. Schuetz, A phase I trial of pox PSA vaccines (PROSTVAC-VF) with
B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with
prostate cancer, Journal of Translational Medicine 4 (2006) 1.
64] P. Specenier, Ipilimumab in melanoma, Expert Review of Anticancer Therapy
(2012).
65] R.A. Madan, M.  Mohebtash, P.M. Arlen, M.  Vergati, M.  Rauckhorst, S.M. Stein-
berg, K.Y. Tsang, D.J. Poole, H.L. Parnes, J.J. Wright, W.L. Dahut, J. Schlom, J.L.
Gulley, Ipilimumab and a poxviral vaccine targeting prostate-speciﬁc antigen
in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation
trial, Lancet Oncology 13 (2012) 501–508.
66] W.L. Dahut, J.L. Gulley, P.M. Arlen, Y. Liu, K.M. Fedenko, S.M. Steinberg, J.J.
Wright, H. Parnes, C.C. Chen, E. Jones, C.E. Parker, W.M.  Linehan, W.D. Figg, Ran-
domized phase II trial of docetaxel plus thalidomide in androgen-independent
prostate cancer, Journal of Clinical Oncology 22 (2004) 2532–2539.
67] D. Keizman, M.  Zahurak, V. Sinibaldi, M.  Carducci, S. Denmeade, C. Drake, R.
Pili,  E.S. Antonarakis, S. Hudock, M.  Eisenberger, Lenalidomide in nonmetastatic
biochemically relapsed prostate cancer: results of a phase I/II double-blinded,
randomized study, Clinical Cancer Research 16 (2010) 5269–5276.
68] B. Adesunloye, X. Huang, J.M. Ning, A. Ravi, J. Madan, J. Beatson, Dual antian-
giogenic therapy using lenalidomide and bevacizumab with docetaxel and
prednisone in patients with metastatic castration-resistant prostate cancer
(mCRPC), Journal of Clinical Oncology 30 (2012) (suppl; abstr 4569), Ref Type:
abstract.
69] P. Carmeliet, R.K. Jain, Angiogenesis in cancer and other diseases, Nature 407
(2000) 249–257.
70] P. Carmeliet, VEGF as a key mediator of angiogenesis in cancer, Oncology 69
(Suppl. 3) (2005) 4–10.
71] G. Di Lorenzo, W.D. Figg, S.D. Fossa, V. Mirone, R. Autorino, N. Longo, C. Imbimbo,
S.  Perdona, A. Giordano, M.  Giuliano, R. Labianca, S. De Placido, Combination
of  bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory
prostate cancer: a phase 2 study, European Urology 54 (2008) 1089–1094.
72] W.K. Kelly, S. Halabi, M. Carducci, D. George, J.F. Mahoney, W.M. Stadler, M.
Morris, P. Kantoff, J.P. Monk, E. Kaplan, N.J. Vogelzang, E.J. Small, Random-
ized, double-blind, placebo-controlled phase III trial comparing docetaxel and
prednisone with or without bevacizumab in men  with metastatic castration-
resistant prostate cancer: CALGB 90401, Journal of Clinical Oncology 30 (2012)
1534–1540.
73] J. Hasskarl, Sorafenib, Recent Results Cancer Research 184 (2010) 61–70.
74] J.B. Aragon-Ching, L. Jain, J.L. Gulley, P.M. Arlen, J.J. Wright, S.M. Steinberg, D.
Draper, J. Venitz, E. Jones, C.C. Chen, W.D. Figg, W.L. Dahut, Final analysis of a
phase II trial using sorafenib for metastatic castration-resistant prostate cancer,
BJU International 103 (2009) 1636–1640.
75] E.K. Beardsley, S.J. Hotte, S. North, S.L. Ellard, E. Winquist, C. Kollmannsberger,
S.D. Mukherjee, K.N. Chi, A phase II study of sorafenib in combination with bica-
lutamide in patients with chemotherapy-naive castration resistant prostate
cancer, Invest New Drugs 30 (2012) 1652–1659.
76] Q.S. Chu, Aﬂibercept (AVE0005): an alternative strategy for inhibiting tumour
angiogenesis by vascular endothelial growth factors, Expert Opinion on Biolog-
ical Therapy 9 (2009) 263–271.
77] G. Sonpavde, P.O. Periman, D. Bernold, D. Weckstein, M.T. Fleming, M.D. Gal-
sky, W.R. Berry, F. Zhan, K.A. Boehm, L. Asmar, T.E. Hutson, Sunitinib malate
for metastatic castration-resistant prostate cancer following docetaxel-based
chemotherapy, Annals of Oncology 21 (2010) 319–324.
78] A.J. Zurita, D.J. George, N.D. Shore, G. Liu, G. Wilding, T.E. Hutson, M.  Kozloff, P.
Mathew, C.S. Harmon, S.L. Wang, I. Chen, E.C. Maneval, C.J. Logothetis, Sunitinib & Molecular Biology 138 (2013) 248– 256
in combination with docetaxel and prednisone in chemotherapy-naive patients
with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial,
Annals of Oncology 23 (2012) 688–694.
79] D. Romero, C. O‘Neill, A. Terzic, L. Contois, K. Young, B.A. Conley, R.C. Bergan,
P.C.  Brooks, C.P. Vary, Endoglin regulates cancer-stromal cell interactions in
prostate tumors, Cancer Research 71 (2011) 3482–3493.
80] L.S. Rosen, H.I. Hurwitz, M.K. Wong, J. Goldman, D.S. Mendelson, W.D. Figg,
S.  Spencer, B.J. Adams, D. Alvarez, B.K. Seon, C.P. Theuer, B.R. Leigh, M.S.
Gordon, A phase I ﬁrst-in-human study of TRC105 (Anti-Endoglin Anti-
body) in patients with advanced cancer, Clinical Cancer Research 18 (2012)
4820–4829.
81] C. Pezaro, M.A. Rosenthal, H. Gurney, I.D. Davis, C. Underhill, M.J. Boyer, D.
Kotasek, B. Solomon, G.C. Toner, An open-label, single-arm phase two trial of
geﬁtinib in patients with advanced or metastatic castration-resistant prostate
cancer, American Journal of Clinical Oncology 32 (2009) 338–341.
82] E.J. Small, J. Fontana, N. Tannir, R.S. DiPaola, G. Wilding, M.  Rubin, R.B.
Iacona, F.F. Kabbinavar, A phase II trial of geﬁtinib in patients with non-
metastatic hormone-refractory prostate cancer, BJU International 100 (2007)
765–769.
83] G. Liu, Y.H. Chen, J. Kolesar, W.  Huang, R. Dipaola, M. Pins, M.  Carducci, M.
Stein, G.J. Bubley, G. Wilding, Eastern cooperative oncology group phase II trial
of  lapatinib in men  with biochemically relapsed, androgen dependent prostate
cancer, Urologic Oncology 31 (2013) 211–218.
84] Y.E. Whang, A.J. Armstrong, W.K. Rathmell, P.A. Godley, W.Y. Kim, R.S. Pruthi,
E.M.  Wallen, J.M. Crane, D.T. Moore, G. Grigson, K. Morris, C.P. Watkins, D.J.
George, A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase
inhibitor, in patients with castration-resistant prostate cancer, Urologic Oncol-
ogy 31 (2013) 82–86.
85] M.T. Fleming, G. Sonpavde, M.  Kolodziej, S. Awasthi, T.E. Hutson, D. Martincic,
A. Rastogi, S.R. Rousey, R.E. Weinstein, M.D. Galsky, W.R. Berry, Y. Wang, K.A.
Boehm, L. Asmar, M.A. Rauch, T.M. Beer, Association of rash with outcomes in a
randomized phase II trial evaluating cetuximab in combination with mitox-
antrone plus prednisone after docetaxel for metastatic castration-resistant
prostate cancer, Clinical Genitourinary Cancer 10 (2012) 6–14.
86] C. Nabhan, D. Villines, T.V. Valdez, K. Tolzien, T.M. Lestingi, J.D. Bitran, S.M.
Christner, M.J. Egorin, J.H. Beumer, Phase I study investigating the safety and
feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients
with refractory castration-resistant prostate cancer, British Journal of Cancer
107  (2012) 592–597.
87] I. Heidegger, A. Pircher, H. Klocker, P. Massoner, Targeting the insulin-like
growth factor network in cancer therapy, Cancer Biology & Therapy 11 (2011)
701–707.
88] E. Seccareccia, P. Brodt, The role of the insulin-like growth factor-I recep-
tor  in malignancy: an update, Growth Hormone & IGF Research 22 (2012)
193–199.
89] M.  Pollak, The insulin and insulin-like growth factor receptor family in neopla-
sia:  an update, Nature Reviews Cancer 12 (2012) 159–169.
90] K.N. Chi, M.E. Gleave, L. Fazli, S.L. Goldenberg, A. So, C. Kollmannsberger, N.
Murray, A. Tinker, M. Pollak, A phase II pharmacodynamic study of preoper-
ative ﬁgitumumab in patients with localized prostate cancer, Clinical Cancer
Research 18 (2012) 3407–3413.
91] R. Kurzrock, S.I. Sherman, D.W. Ball, A.A. Forastiere, R.B. Cohen, R. Mehra, D.G.
Pﬁster, E.E. Cohen, L. Janisch, F. Nauling, D.S. Hong, C.S. Ng, L. Ye, R.F. Gagel, J.
Frye, T. Muller, M.J. Ratain, R. Salgia, Activity of XL184 (Cabozantinib), an oral
tyrosine kinase inhibitor, in patients with medullary thyroid cancer, Journal of
Clinical Oncology 29 (2011) 2660–2666.
92] D.C. Smith, M.R. Smith, C. Sweeney, A.A. Elﬁky, C. Logothetis, P.G. Corn, N.J.
Vogelzang, E.J. Small, A.L. Harzstark, M.S. Gordon, U.N. Vaishampayan, N.B.
Haas, A.I. Spira, P.N. Lara, C.C. Lin Jr., S. Srinivas, A. Sella, P. Schoffski, C. Scheffold,
A.L. Weitzman, M. Hussain, Cabozantinib in patients with advanced prostate
cancer: results of a phase II randomized discontinuation trial, Journal of Clinical
Oncology 31 (2013) 412–419.
93] J.S. De Bono, S. Oudard, M.  Ozguroglu, S. Hansen, J.P. Machiels, I. Kocak, G. Gravis,
I.  Bodrogi, M.J. Mackenzie, L. Shen, M.  Roessner, S. Gupta, A.O. Sartor, Prednisone
plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate
cancer progressing after docetaxel treatment: a randomised open-label trial,
Lancet 376 (2010) 1147–1154.
94] A. Heidenreich, H.J. Scholz, S. Rogenhofer, C. Arsov, M. Retz, S.C. Muller, P. Albers,
J.  Gschwend, M.  Wirth, U. Steiner, K. Miller, E. Heinrich, L. Trojan, B. Volkmer,
F.  Honecker, C. Bokemeyer, B. Keck, B. Otremba, E. Ecstein-Fraisse, D. Pﬁster,
Cabazitaxel plus prednisone for metastatic castration-resistant prostate can-
cer  progressing after docetaxel: results from the German compassionate-use
programme, European Urology 63 (2013) 977–982.
